The anti-IgLON5 disease retweeted
MOGAD-like, but MOG-IgG negative? 🧠
Very happy to see our work out in @GreenJournal
@GemmaOlivé and @ThaisArmangué!!!
Children with MOG-IgG-negative encephalitis showed a similar clinical/MRI phenotype and response to immunotherapy, but fewer relapses (3% vs 18%).
Children can develop the full spectrum of MOGAD-like encephalitis without MOG-IgG. Clinical features and immunotherapy response are similar to MOGAD, but relapses are uncommon: hubs.la/Q04vrm6_0
The anti-IgLON5 disease retweeted
Time to go home!
After an incredible period at @MayoClinicNeuro, today I'm starting a new chapter at @hospitalclinic / @neuroimmuclinic, joining the neuroimmunology lab of Josep Dalmau.
Hospital Clinic (@UniBarcelona) is where I trained as a student and where I always felt like home!
To everyone at Mayo: thank you! I learned from some of the greatest neurologists I've ever met, and I leave with mentors, collaborators and friends for life. This is not goodbye, just the start of a transatlantic collaboration!
Excited for what's next in autoimmune neurology! 🧠
#Neurology #Neuroimmunology
The anti-IgLON5 disease retweeted
We have a great new issue for you! Want to hear how the role of neurology chair is evolving? Or learn more about anti-IGLON5 disease? Read on for that and much more: hubs.la/Q04xP4_f0
#NeuroTwitter #neurology
The anti-IgLON5 disease retweeted
Become an @ISNI_neuro member now to be eligible for travel awards to
join us in beautiful Venice. More update on the program soon. #WeAreNeuroimmunology
Make the most of your experience at the 18th International Congress of Neuroimmunology in Venice.
ISNI members enjoy:
• Reduced Congress registration rates
• Eligibility to apply for Travel Awards
• Early access to registration
Complimentary membership is available for all new and renewing members through the end of 2026, so you can start taking advantage of these benefits today.
🔗 Become a member: isniweb.org/become-a-member
#WeAreNeuroimmunology #Neuroimmunology #ISNICongress2027
The anti-IgLON5 disease retweeted
A new study of anti-IgLON5 disease has brought into focus the need for neurologists to consider it in their differential diagnoses: hubs.la/Q04xST1s0
#NeuroTwitter #autoimmune @AlbertoEspay @idibaps
The anti-IgLON5 disease retweeted
Facing #autoimmuneencephalitis? You're not alone. Discover vital insights from the SAPIENCE study on #caregiver experiences & importance of early diagnosis. Join the conversation on improving long-term support and awareness. 🙌 Read more: autoimmune-encephalitis.org/…
Aquesta setmana, a l'IDIBAPS...
El projecte europeu #IGNITION, coordinat des de #IDIBAPS, tanca la seva convocatòria amb una destacada resposta internacional
560 candidatures de 64 països opten a les 13 places de doctorat
👉f.mtr.cool/gvvtsholyj
The anti-IgLON5 disease retweeted
Don't miss this opportunity! – at Barcelona, Spain
📢 We are #hiring #phd at IGNITION.
13 positions: Spain, Portugal, France, Italy, Germany, Poland, The Netherlands, Austria.
Meet our associated partner Sonja Noss. Discover the Growtential and smartfullness with us sonjanoss.com/
Apply: ignition-consortium.eu
The anti-IgLON5 disease retweeted
El Dr Carges Gaig nos hace una revisión sobre la enfermedad por anticuerpos anti-IgLON5.
The anti-IgLON5 disease retweeted
Replying to @josemariacm_
@josemariacm_ , de nuestra unidad, cierra el curso presentando los resultados del estudio Neuro-CART-Spain, sobre ICANS asociado a terapia CAR T anti-CD19 en España.
Calor, tacte i dolor: com ho detecten les nostres neurones?
Cicle de xerrades divulgatives 'A la recerca de la salut'
👨🔬Xavier Gasull
📆17/3
⏰ 11:00
📍 Casa Golferichs @ccgolferichs
👉f.mtr.cool/ywcwgroqwc
The anti-IgLON5 disease retweeted
We’re now on Bluesky!
You will find:
🔬 EU-funded science news & breakthroughs
💰 Calls, tenders & funding tips (Horizon Europe, ERC, MSCA…)
🚀 Projects growing from TRL 1 to market-ready
📊 Tools & resources for researchers
Join the conversation: bsky.app/profile/scienceinno…
The anti-IgLON5 disease retweeted
Honored to present Dr. Frank Leypoldt as our keynote on #AutoimmuneEncephalitis — a rare chance to hear a world-class neuroimmunologist & GENERATE leader. Inspiring insights on LGI1, IgLON5 & future therapies. 🔗 👉 youtu.be/GnXwOCy7_J0 Subscribe & hit the bell! #Neurology
The anti-IgLON5 disease retweeted
Replying to @idibaps
@idibaps @hospitalclinic @ThePhDPlace @PhD_genie @TheStrugglingS4 @ScholarshipfPhd Do you like neuroscience? 🧠🧠🧠🧠🧠. We have 13 fully funded #phd positions by @EU_Commission MSCA-DN. Apply through our web👉: ignition-consortium.eu 👨🎓👩🎓🚀
The anti-IgLON5 disease retweeted
Honored to present Dr. Frank Leypoldt as our keynote on #AutoimmuneEncephalitis — a rare chance to hear a world-class neuroimmunologist & GENERATE leader. Inspiring insights on LGI1, IgLON5 & future therapies. 🔗 👉 youtu.be/GnXwOCy7_J0 Subscribe & hit the bell! #Neurology
The anti-IgLON5 disease retweeted
Let me explain IGNITION consortium's logo: Two hemispheres of the #brain 🧠.
One 🚀 IGNITION rocket-antibodies against @iglon5
The other half, containing neurodegeneration. Let's solve this mistery together🔎. Apply for the #PhDposition fully funded by EU #MSCA-DN actions
The anti-IgLON5 disease retweeted
Have you hear about IGNITION and anti-IgLON5 disease? @iglon5.
We have a web ignition-consortium.eu
We have a linkedin page
linkedin.com/ignition-consor…
If you want a successful #career and a #PhD #PhDposition, then apply!. We need you in our
#MSCA consortium
🚀🔥🧠👩🎓👨🎓🌍
Replying to @andreuvilaseca7 @Brain1878
An intriguing point about IgLON5! The correlation between IgG4 antibodies and tau pathology is a compelling area of research, especially with the ability to replicate in vitro. What implications could this have for early diagnostic markers or therapeutic targets? It’s fascinating to see how these molecular interactions could redefine our understanding of neurodegenerative disease progression. For more on this topic, Sci-Quest is an excellent resource for generating comprehensive biomedical reviews. Check it out [here](sciqst.com) for more insights. #Neurology #Medicine
































